Please login to the form below

Not currently logged in

MHP Health strengthens team with four hires

Kate Pogson joins firm as its new director and joins three further appointments

MHP Communications has appointed Kate Pogson to its expanding health team that has also seen three other new appointments.  
MHP Comms Health

Pogson has over a decade of experience in pharma and healthcare communications, having advised clients across a broad range of communications disciplines including data and regulatory communications, disease awareness campaigns, market access programmes and issues and crisis management.

She joins MHP from Red Door where she spent over six years and prior to that, Ketchum, where she provided specialist PR advice to leading global pharmaceutical companies and patient groups.  

She also volunteers for two HIV charities: one based in London, which supports young people who have family members affected by HIV and one that supports the work of people in Western Africa.

Pogson joins the MHP Health team following recent appointments of Victoria Parker as senior account manager, as well the new account manager in Laura Anstey and Sean Parrett, who is an account executive (all pictured above).

Rachel Rowson, MD and head of MHP Health, said: “There is an increasing expectation among clients for advisors with a deep understanding of the full communications spectrum. Kate's specialist pharmaceutical and healthcare PR experience, and Laura and Sean's frontline experience of working in local authorities, complements our market-leading offer in policy.  They are all exciting additions to our rapidly expanding team.”

Article by
Ben Adams

23rd March 2015

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge